Cytisiniclin "2care4"

{
  "EntityId": "10906",
  "LastUpdated": "2026-07-17T00:32:47.044427\u002B02:00",
  "LastRevisedDate": {
    "Header": "Revisionsdato",
    "Value": "\u003Cdiv id=\u0022revisionsdato\u0022\u003E\u003Cp\u003E\u003Cspan class=\u0022dato\u0022\u003EFredag den 14. november 2025\u003C/span\u003E. Priserne er dog g\u00E6ldende pr.\u003Cspan class=\u0022dato\u0022\u003Emandag den 6. juli 2026.\u003C/span\u003E\u003Cdiv class=\u0022smalltext\u0022\u003EDer kan forekomme forskelle mellem pr\u00E6paratbeskrivelsen og oplysningerne i produktresumeet og/eller indl\u00E6gssedlen. Det skyldes, at min.medicin.dk kan have suppleret L\u00E6gemiddelstyrelsens og producentens pr\u00E6paratinformationer med andre kilder. Min.medicin.dk har det fulde ansvar for pr\u00E6paratbeskrivelserne.\u003C/div\u003E\u003C/p\u003E\u003C/div\u003E"
  },
  "MedicineName": {
    "Header": "Pr\u00E6paratnavn",
    "Value": "Cytisiniclin \u00222care4\u0022"
  },
  "TradeNames": {
    "Header": "Handelsnavne",
    "Value": []
  },
  "Slug": "cytisiniclin-2care4",
  "CompanyName": {
    "Header": "Firmanavn",
    "Value": "Parallelimport"
  },
  "Usage": {
    "Header": "Bruges mod",
    "Value": "\u003Cdiv id=\u0022anvendelse\u0022\u003E\u003Cp\u003ECytisiniclin \u00222care4\u0022 er et middel til hj\u00E6lp ved rygeoph\u00F8r.\u003C/p\u003E\u003C/div\u003E"
  },
  "Dosage": {
    "Header": "Dosering",
    "Value": "\u003Cdiv id=\u0022doseringsforslag\u0022\u003E\u003Cp\u003EFindes som tabletter.\u003C/p\u003E\u003Cp\u003E\u003Cb\u003EVoksne.\u003C/b\u003E Tages normalt som et behandlingsforl\u00F8b p\u00E5 25 dage efter nedenst\u00E5ende plan: \u003C/p\u003E\u003Ctable border=\u00220\u0022 bordercolor=\u0022#aaaaaa\u0022 cellpadding=\u00220\u0022 cellspacing=\u00220\u0022 class=\u0022pipTable\u0022 style=\u0022border-collapse:collapse;\u0022 width=\u0022100%\u0022\u003E\u003Ctr class=\u0022Header\u0022\u003E\u003Ctd align=\u0022center\u0022 class=\u0022TableBorder\u0022 valign=\u0022top\u0022 width=\u0022301.5pt\u0022\u003E\u003Cp\u003E\u003Cb\u003EBehandlingsdag \u003C/b\u003E\u003C/p\u003E\u003C/td\u003E\u003Ctd align=\u0022center\u0022 class=\u0022TableBorder\u0022 valign=\u0022top\u0022 width=\u0022301.5pt\u0022\u003E\u003Cp\u003E\u003Cb\u003EAnbefalet dosering \u003C/b\u003E\u003C/p\u003E\u003C/td\u003E\u003Ctd align=\u0022center\u0022 class=\u0022TableBorder\u0022 valign=\u0022top\u0022 width=\u0022301.5pt\u0022\u003E\u003Cp\u003E\u003Cb\u003EH\u00F8jest daglige dosis \u003C/b\u003E\u003C/p\u003E\u003C/td\u003E\u003C/tr\u003E\u003Ctr\u003E\u003Ctd align=\u0022left\u0022 class=\u0022TableBorder\u0022 valign=\u0022top\u0022 width=\u0022301.5pt\u0022\u003E\u003Cp\u003E\u003Cb\u003E1. til 3. dag\u003C/b\u003E\u003C/p\u003E\u003C/td\u003E\u003Ctd align=\u0022left\u0022 class=\u0022TableBorder\u0022 valign=\u0022top\u0022 width=\u0022301.5pt\u0022\u003E\u003Cp\u003E1 tablet hver 2. time\u003C/p\u003E\u003C/td\u003E\u003Ctd align=\u0022left\u0022 class=\u0022TableBorder\u0022 valign=\u0022top\u0022 width=\u0022301.5pt\u0022\u003E\u003Cp\u003E6 tabletter (9 mg)\u003C/p\u003E\u003C/td\u003E\u003C/tr\u003E\u003Ctr\u003E\u003Ctd align=\u0022left\u0022 class=\u0022TableBorder\u0022 valign=\u0022top\u0022 width=\u0022301.5pt\u0022\u003E\u003Cp\u003E\u003Cb\u003E4. til 12. dag\u003C/b\u003E\u003C/p\u003E\u003C/td\u003E\u003Ctd align=\u0022left\u0022 class=\u0022TableBorder\u0022 valign=\u0022top\u0022 width=\u0022301.5pt\u0022\u003E\u003Cp\u003E1 tablet hver 2,5. time\u003C/p\u003E\u003C/td\u003E\u003Ctd align=\u0022left\u0022 class=\u0022TableBorder\u0022 valign=\u0022top\u0022 width=\u0022301.5pt\u0022\u003E\u003Cp\u003E5 tabletter (7,5 mg)\u003C/p\u003E\u003C/td\u003E\u003C/tr\u003E\u003Ctr\u003E\u003Ctd align=\u0022left\u0022 class=\u0022TableBorder\u0022 valign=\u0022top\u0022 width=\u0022301.5pt\u0022\u003E\u003Cp\u003E\u003Cb\u003E13. til 16. dag\u003C/b\u003E\u003C/p\u003E\u003C/td\u003E\u003Ctd align=\u0022left\u0022 class=\u0022TableBorder\u0022 valign=\u0022top\u0022 width=\u0022301.5pt\u0022\u003E\u003Cp\u003E1 tablet hver 3. time\u003C/p\u003E\u003C/td\u003E\u003Ctd align=\u0022left\u0022 class=\u0022TableBorder\u0022 valign=\u0022top\u0022 width=\u0022301.5pt\u0022\u003E\u003Cp\u003E4 tabletter (6 mg)\u003C/p\u003E\u003C/td\u003E\u003C/tr\u003E\u003Ctr\u003E\u003Ctd align=\u0022left\u0022 class=\u0022TableBorder\u0022 valign=\u0022top\u0022 width=\u0022301.5pt\u0022\u003E\u003Cp\u003E\u003Cb\u003E17. til 20. dag\u003C/b\u003E\u003C/p\u003E\u003C/td\u003E\u003Ctd align=\u0022left\u0022 class=\u0022TableBorder\u0022 valign=\u0022top\u0022 width=\u0022301.5pt\u0022\u003E\u003Cp\u003E1 tablet hver 5. time\u003C/p\u003E\u003C/td\u003E\u003Ctd align=\u0022left\u0022 class=\u0022TableBorder\u0022 valign=\u0022top\u0022 width=\u0022301.5pt\u0022\u003E\u003Cp\u003E3 tabletter (4,5 mg)\u003C/p\u003E\u003C/td\u003E\u003C/tr\u003E\u003Ctr\u003E\u003Ctd align=\u0022left\u0022 class=\u0022TableBorder\u0022 valign=\u0022top\u0022 width=\u0022301.5pt\u0022\u003E\u003Cp\u003E\u003Cb\u003E21. til 25. dag\u003C/b\u003E\u003C/p\u003E\u003C/td\u003E\u003Ctd align=\u0022left\u0022 class=\u0022TableBorder\u0022 valign=\u0022top\u0022 width=\u0022301.5pt\u0022\u003E\u003Cp\u003E1-2 tabletter dagligt\u003C/p\u003E\u003C/td\u003E\u003Ctd align=\u0022left\u0022 class=\u0022TableBorder\u0022 valign=\u0022top\u0022 width=\u0022301.5pt\u0022\u003E\u003Cp\u003E2 tabletter (3 mg)\u003C/p\u003E\u003C/td\u003E\u003C/tr\u003E\u003C/table\u003E\u003Cp\u003E\u003Cb\u003EBem\u00E6rk:\u003C/b\u003E\u003C/p\u003E\u003Cul\u003E\u003Cli\u003EDoseringen fordeles over de v\u00E5gne timer. \u003C/li\u003E\u003Cli\u003EDu b\u00F8r stoppe med at ryge senest p\u00E5 femte dagen efter ovenst\u00E5ende behandlingsplan. \u003C/li\u003E\u003Cli\u003EHvis du ikke har effekt af behandlingen, b\u00F8r den afbrydes. Du kan evt. genoptage behandlingen igen efter 2-3 m\u00E5neder. \u003C/li\u003E\u003Cli\u003EIngen erfaring vedr. \u00E6ldre over 65 \u00E5r. \u003C/li\u003E\u003C/ul\u003E\u003Cbr/\u003E\u003C/div\u003E"
  },
  "HowToUse": {
    "Header": "S\u00E5dan tager du medicinen",
    "Value": {
      "KnuseDeleInformation": {
        "Header": "H\u00E5ndtering",
        "Value": "\u003Cdiv id=\u0022KnuseDeleInformation\u0022\u003E\u003Cp\u003E\u003Cdiv\u003E\u003Ch4\u003E\u003Cspan data-drugid=\u002228107098524\u0022\u003E\u003Cb\u003ETabletter 1,5 mg\u003C/b\u003E\u003C/span\u003E\u003Cbr/\u003E\u003C/h4\u003E\u003Cbr/\u003E\u003Cb\u003EMad og drikke\u003C/b\u003E\u003Cdiv\u003ETages med et glas vand\u003C/div\u003E\u003Cbr/\u003E\u003Cb\u003EKnusning/\u00E5bning\u003C/b\u003E\u003Cdiv\u003EM\u00E5 ikke knuses\u003C/div\u003E\u003C/div\u003E\u003C/p\u003E\u003C/div\u003E"
      },
      "Termination": {
        "Header": "Stop af behandling",
        "Value": null
      },
      "MissedDose": {
        "Header": "Glemt medicin",
        "Value": "\u003Cdiv id=\u0022glemtmedicin\u0022\u003E\u003Cul\u003E\u003Cli\u003EForts\u00E6t med n\u00E6ste dosis if\u00F8lge planen.\u003C/li\u003E\u003Cli\u003EDu m\u00E5 ikke tage dobbeltdosis som erstatning for den glemte dosis.\u003C/li\u003E\u003C/ul\u003E\u003C/div\u003E"
      }
    }
  },
  "Precautions": {
    "Header": "Det skal du vide, n\u00E5r du tager medicinen",
    "Value": {
      "Contraindications": {
        "Header": "Hvorn\u00E5r m\u00E5 du ikke tage medicinen?",
        "Value": "\u003Cdiv id=\u0022boerikkeanvendes\u0022\u003E\u003Cp\u003EPga. risiko for forh\u00F8jet blodtryk og p\u00E5virkning af hjertet skal man undg\u00E5 at tage Cytisiniclin \u00222care4\u0022, hvis man: \u003C/p\u003E\u003Cul\u003E\u003Cli\u003Elider af visse typer hjertekrampe (angina pectoris)\u003C/li\u003E\u003Cli\u003Efor nyligt har haft en blodprop i hjertet (myokardieinfarkt)\u003C/li\u003E\u003Cli\u003Ehar alvorlige forstyrrelser af hjerterytmen\u003C/li\u003E\u003Cli\u003Efor nyligt har haft en bl\u00F8dning eller blodprop i hjernen.\u003C/li\u003E\u003C/ul\u003E\u003C/div\u003E"
      },
      "RulesOfCaution": {
        "Header": "S\u00E6rlige advarsler",
        "Value": "\u003Cdiv id=\u0022saerligeadvarsler\u0022\u003E\u003Cp\u003E\u003Cb\u003EFortsat rygning eller brug af nicotinholdige produkter\u003C/b\u003E\u003C/p\u003E\u003Cp\u003EDer kan v\u00E6re \u00F8get risiko for bivirkninger, hvis du forts\u00E6tter med at ryge eller bruger produkter med nicotin under behandlingen.\u003C/p\u003E\u003Cp\u003E\u003Cb\u003EPsykiske symptomer\u003C/b\u003E\u003C/p\u003E\u003Cp\u003EEn r\u00E6kke psykiske symptomer (bl.a. aggressivitet, angst, depression, psykoser, selvmordsadf\u00E6rd) er set ved rygeoph\u00F8r - b\u00E5de med og uden brug af hj\u00E6lpemidler. Symptomerne ses oftere, hvis man tidligere har haft psykiske lidelser.\u003C/p\u003E\u003Cp\u003E\u003Cb\u003ETilstande, der kan p\u00E5virkes af, eller \u00F8ge risikoen for, evt. bivirkninger:\u003C/b\u003E\u003C/p\u003E\u003Cul\u003E\u003Cli\u003EDiabetes\u003C/li\u003E\u003Cli\u003EFor h\u00F8jt stofskifte\u003C/li\u003E\u003Cli\u003EVisse typer sygdom i hjertet, fx blodprop i hjertet\u003C/li\u003E\u003Cli\u003EFor h\u00F8jt blodtryk\u003C/li\u003E\u003Cli\u003ESvulst i binyremarven (f\u00E6okromocytom) \u003C/li\u003E\u003Cli\u003E\u00C5reforkalkning eller andre sygdomme i blodkarrene \u003C/li\u003E\u003Cli\u003EHalsbrand (refluks)\u003C/li\u003E\u003Cli\u003ES\u00E5r i mave-tarm-kanalen.\u003C/li\u003E\u003C/ul\u003E\u003C/div\u003E"
      },
      "Interactions": {
        "Header": "Brug af anden medicin",
        "Value": null
      },
      "Pregnancy": {
        "Header": "Graviditet og fertilitet",
        "Value": "\u003Cdiv id=\u0022graviditet\u0022\u003EB\u00F8r ikke anvendes pga. manglende viden. Denne tekst afviger fra firmaets godkendte produktinformation (produktresum\u00E9).\u003C/div\u003E"
      },
      "Lactation": {
        "Header": "Amning",
        "Value": "\u003Cdiv id=\u0022amning\u0022\u003EB\u00F8r ikke anvendes pga. manglende viden. Denne tekst afviger fra firmaets godkendte produktinformation (produktresum\u00E9).\u003C/div\u003E"
      },
      "Alchohol": {
        "Header": "Alkohol",
        "Value": "\u003Cdiv id=\u0022alkohol\u0022\u003E\u003Cp\u003E\u003Cp\u003EAlkohol og Cytisiniclin \u00222care4\u0022 p\u00E5virker ikke hinanden.\u003C/p\u003E\u003Cp\u003EF\u00F8lg dog altid Sundhedsstyrelsens anbefalinger om genstandsgr\u00E6nser.\u003C/p\u003E\u003C/p\u003E\u003C/div\u003E"
      },
      "BloodDonor": {
        "Header": "Bloddonor",
        "Value": "\u003Cdiv id=\u0022bloddonor\u0022\u003EM\u00E5 ikke tappes. 1 d\u00F8gns karant\u00E6ne.\u003C/div\u003E"
      },
      "Doping": {
        "Header": "Doping",
        "Value": null
      },
      "Traffic": {
        "Header": "Trafik",
        "Value": null
      },
      "SchengenCertificate": {
        "Header": "Schengenattest (pillepas)",
        "Value": null
      },
      "ShelfLifeAndStorage": {
        "Header": "Holdbarhed og opbevaring",
        "Value": null
      }
    }
  },
  "SideEffects": {
    "Header": "Bivirkninger",
    "Value": {
      "VeryCommon": {
        "Header": "Meget almindelige",
        "Comment": "Flere end 10 ud af 100 personer f\u00E5r bivirkningen.",
        "Value": {
          "SeriousAdverseReactions": {
            "Header": "Potentielt alvorlige bivirkninger",
            "Value": [
              "Mavesmerter",
              "Svimmelhed",
              "Angst",
              "Hum\u00F8rsvingninger",
              "Forh\u00F8jet blodtryk"
            ]
          },
          "NonSeriousAdverseReactions": {
            "Header": "Oftest ikke alvorlige bivirkninger",
            "Value": [
              "Hurtig hjerterytme",
              "Forstoppelse",
              "Kvalme",
              "Mundt\u00F8rhed",
              "Opkastning",
              "Smagsforstyrrelser",
              "Sure opst\u00F8d",
              "Kraftesl\u00F8shed",
              "V\u00E6gt\u00F8gning",
              "Appetitforstyrrelser (oftest \u00F8get)",
              "Muskelsmerter",
              "Hovedpine",
              "Irritabilitet",
              "S\u00F8vnforstyrrelser",
              "Hududsl\u00E6t"
            ]
          }
        }
      },
      "Common": {
        "Header": "Almindelige",
        "Comment": "H\u00F8jst 10 ud af 100 personer f\u00E5r bivirkningen.",
        "Value": {
          "SeriousAdverseReactions": {
            "Header": "Potentielt alvorlige bivirkninger",
            "Value": [
              "Langsom puls",
              "Koncentrationsbesv\u00E6r"
            ]
          },
          "NonSeriousAdverseReactions": {
            "Header": "Oftest ikke alvorlige bivirkninger",
            "Value": [
              "Br\u00E6ndende fornemmelse p\u00E5 tungen",
              "Diarr\u00E9",
              "Oppustethed",
              "Utilpashed"
            ]
          }
        }
      },
      "Uncommon": {
        "Header": "Ikke almindelige",
        "Comment": "H\u00F8jst 1 ud af 100 personer f\u00E5r bivirkningen.",
        "Value": {
          "SeriousAdverseReactions": {
            "Header": "Potentielt alvorlige bivirkninger",
            "Value": [
              "Leverp\u00E5virkning"
            ]
          },
          "NonSeriousAdverseReactions": {
            "Header": "Oftest ikke alvorlige bivirkninger",
            "Value": [
              "\u00D8get spytdannelse",
              "Tr\u00E6thed",
              "Nedsat sexlyst",
              "Tynd hud",
              "\u00D8get svedtendens"
            ]
          }
        }
      },
      "Rare": {
        "Header": "Sj\u00E6ldne",
        "Comment": null,
        "Value": {
          "SeriousAdverseReactions": {
            "Header": "Potentielt alvorlige bivirkninger",
            "Value": []
          },
          "NonSeriousAdverseReactions": {
            "Header": "Oftest ikke alvorlige bivirkninger",
            "Value": []
          }
        }
      },
      "VeryRare": {
        "Header": "Meget sj\u00E6ldne",
        "Comment": null,
        "Value": {
          "SeriousAdverseReactions": {
            "Header": "Potentielt alvorlige bivirkninger",
            "Value": []
          },
          "NonSeriousAdverseReactions": {
            "Header": "Oftest ikke alvorlige bivirkninger",
            "Value": []
          }
        }
      },
      "FrequencyNotKnown": {
        "Header": "Ikke kendt",
        "Comment": null,
        "Value": {
          "SeriousAdverseReactions": {
            "Header": "Potentielt alvorlige bivirkninger",
            "Value": []
          },
          "NonSeriousAdverseReactions": {
            "Header": "Oftest ikke alvorlige bivirkninger",
            "Value": []
          }
        }
      }
    },
    "AdditionalSideEffectsText": "\u003Cul\u003E\u003Cli\u003ERygeoph\u00F8r kan i sig selv give en r\u00E6kke symptomer, og det kan v\u00E6re vanskeligt at skelne mellem disse symptomer og bivirkninger ved behandling med Cytisiniclin \u00222care4\u0022.\u003C/li\u003E\u003C/ul\u003E"
  },
  "ActiveSubstances": {
    "Header": "Virksomme stoffer",
    "Value": [
      {
        "Name": "Cytisin"
      }
    ]
  },
  "Products": {
    "Header": "Priser, pakninger og tilskud",
    "Value": [
      {
        "ProductNumber": "180496",
        "DisplayName": "Cytisiniclin \u00222care4\u0022 1,5 mg / 100 stk.",
        "Packaging": "100 stk.",
        "Price": 555.0,
        "PricePerUnit": 5.55,
        "TradeName": "Cytisiniclin \u00222care4\u0022",
        "PharmaceuticalForm": "Tabletter",
        "DrugStrength": "1,5 mg",
        "Dispensing": "Receptpligtigt, flere udleveringer",
        "Reimbursement": "Generelt medicintilskud",
        "ExpirationDate": null,
        "IsVariablePrice": false,
        "Substitutes": [
          {
            "ProductNumber": "381523",
            "Slug": "decigatan",
            "DisplayName": "Decigatan 1,5 mg / 100 stk. (blister)",
            "Price": 533.35,
            "PricePerUnit": 5.33,
            "SubstitutionPriceGroup": "A",
            "ExpirationDate": null,
            "IsVariablePrice": false
          },
          {
            "ProductNumber": "447216",
            "Slug": "cytisiniclin-orifarm",
            "DisplayName": "Cytisiniclin \u0022Orifarm\u0022 1,5 mg / 100 stk. (blister)",
            "Price": 570.1,
            "PricePerUnit": 5.7,
            "SubstitutionPriceGroup": "C",
            "ExpirationDate": null,
            "IsVariablePrice": false
          }
        ]
      }
    ]
  },
  "Excipients": {
    "Header": "Hj\u00E6lpestoffer",
    "Value": [
      "\u003Cdiv id=\u0022hjaelpestoffer\u0022\u003E\u003Cp\u003E\u003Cb\u003EAndre:\u003C/b\u003E\u003C/p\u003E\u003Cspan class=\u0022navn\u0022\u003EGlyceroldibehenat\u003C/span\u003E : \u003Cspan class=\u0022dispenseringsformogstyrke\u0022\u003Etabletter 1,5 mg\u003C/span\u003E\u003Cbr/\u003E\u003Cspan class=\u0022navn\u0022\u003EHypromellose\u003C/span\u003E : \u003Cspan class=\u0022dispenseringsformogstyrke\u0022\u003Etabletter 1,5 mg\u003C/span\u003E\u003Cbr/\u003E\u003Cspan class=\u0022navn\u0022\u003EMagnesiumstearat\u003C/span\u003E : \u003Cspan class=\u0022dispenseringsformogstyrke\u0022\u003Etabletter 1,5 mg\u003C/span\u003E\u003Cbr/\u003E\u003Cspan class=\u0022navn\u0022\u003EMannitol (E-421)\u003C/span\u003E : \u003Cspan class=\u0022dispenseringsformogstyrke\u0022\u003Etabletter 1,5 mg\u003C/span\u003E\u003Cbr/\u003E\u003Cspan class=\u0022navn\u0022\u003EMikrokrystallinsk cellulose\u003C/span\u003E : \u003Cspan class=\u0022dispenseringsformogstyrke\u0022\u003Etabletter 1,5 mg\u003C/span\u003E\u003C/div\u003E"
    ]
  },
  "PharmacologicalEffect": {
    "Header": "S\u00E5dan virker medicinen",
    "Value": "\u003Cdiv id=\u0022virkning\u0022\u003E\u003Cul\u003E\u003Cli\u003EVirker ved at p\u00E5virke bestemte receptorer i hjernen, s\u00E5 abstinenssymptomerne ved rygeoph\u00F8r mindskes. \u003C/li\u003E\u003Cli\u003EHalveringstiden i blodet (T\u00BD) er ca. 4 timer.\u003C/li\u003E\u003C/ul\u003E\u003C/div\u003E"
  },
  "Reimbursement": {
    "Header": "Tilskud",
    "Value": null
  }
}